FIELD: medicine.
SUBSTANCE: in the patients diagnosed with breast cancer and recommended to have a chemotherapeutic course, the heart rate is measured one week before the treatment according to electrocardiography after a 5-minute rest. If the measured heart rate is 70 beats per minute or more, ivabradine is prescribed in a daily dose of 10 mg. Electrocardiography is repeated after a 5-minute rest 4 weeks later. If the measured heart rate is 70 beats per minute or more, the dose is titration is made to 15 mg a day. If the measured follow-up heart rate is less than 70 beats per minute, the daily dose is kept at 10 mg. If the initial heart rate is less than 70 beats per minute, trimetasidine is prescribed in a daily dose of 70 mg for the whole period of treatment independent from the further heart rate measurement. All the patients take the preparation throughout the duration of 6 months.
EFFECT: method enables reducing the cardiotoxic action of the anthracycline chemopreparations in the patients with breast cancer.
3 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING PROGRESSION OF ANTHRACYCLINE-INDUCED CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER WITHIN 24 MONTHS | 2022 |
|
RU2793672C1 |
| METHOD FOR PREDICTION OF SUBACUTE ANTHRACYCLINE-MEDIATED CARDIOTOXICITY DEVELOPMENT IN ONCOLOGICAL PATIENTS | 2020 |
|
RU2744682C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER WITHIN 12 MONTHS AFTER CHEMOTHERAPY WITH ANTRACYCLIC DRUGS | 2018 |
|
RU2680139C1 |
| METHOD FOR PREDICTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN WOMEN WITH BREAST CANCER | 2019 |
|
RU2714683C1 |
| METHOD FOR PERSONALIZED SELECTION OF PATIENTS WITH ANTHRACYCLINE-INDUCED CARDIOMYOPATHY AFTER POLYCHEMOTHERAPY OF BREAST CANCER FOR EFFECTIVE TREATMENT WITH CARVEDILOL | 2021 |
|
RU2778612C1 |
| METHOD FOR PREDICTION OF CUMMULATIVE CARDIAC TOXICITY OF CHEMOTHERAPEUTIC PREPARATIONS | 2012 |
|
RU2510240C2 |
| METHOD FOR PREDICTING THE PROGRESSION OF CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER AFTER ANTHRACYCLINE CHEMOTHERAPY | 2022 |
|
RU2790788C1 |
| METHOD FOR EXTRACORPORAL SHOCK-WAVE HEART THERAPY IN CASE OF ISCHEMIC HEART DISEASE | 2017 |
|
RU2638451C1 |
| METHOD FOR ASSESSING SUBCLINICAL CARDIOTOXICITY OF CHEMO- AND TARGETED THERAPY USING ECHOCARDIOGRAPHIC DIAGNOSTICS | 2022 |
|
RU2815813C1 |
| 3-(1H-BENZIMIDAZOL-2-YL) -1,2,2-TRIMETHYL CYCLOPENTANCARBONIC ACID WITH CARDIOPROTECTIVE ACTIVITY | 2017 |
|
RU2645356C1 |
